腫瘍由来のEBI3は,胃がんにおけるSTAT4-IL-10/CCL5経由によるCD8+T細胞枯渇を促進する
Yong-Jia Yan1, Xin Liu1, Daohan Wang1
1Tianjin Medical University General Hospital, Tianjin, China.
Cancer immunology research
|September 1, 2025
まとめ
エピジェネティックレギュレータEBI3は,胃がん (GC) のT細胞枯渇を促進し,免疫療法を阻害する. 抗EBI3ペプチドが開発され,この疲労を逆転させ,GC患者にとって新しい治療戦略を提供しました.
科学分野:
- 腫瘍学
- 免疫学
- 分子生物学
背景:
- 進行した胃がん (GC) の治療には,化学療法と免疫療法が併用されます.
- 腫瘍の微小環境におけるT細胞の枯渇は,免疫療法の有効性を制限する.
- T細胞枯渇のメカニズムの理解は,GC治療の結果を改善するために不可欠です.
研究 の 目的:
- GCにおけるT細胞枯渇を促進するEBI3の役割を調査する.
- EBI3がT細胞の疲労を誘発する分子メカニズムを解明する.
- EBI3を標的とした治療薬を開発し,抗腫瘍免疫を強化する.
主な方法:
- GC患者の臨床病理学的特徴とのEBI3発現の相関分析
- トランスクリプトームの配列化とマウスのGCモデルでT細胞の枯渇を評価する.
- EBI3に曝されたCD8+T細胞のインビトロおよびインビボ試験
- 抗EBI3ヘプタペプチドの開発と試験
主要な成果:
- EBI3はGCで高く表現され,進行した腫瘍の段階と分化に関連しています.
- EBI3の発現はCD8+T細胞の疲労と相関しており,シトカインの分泌が減少し,抑制受容体が増加することが特徴です.
- EBI3はSTAT4のリン酸化によってT細胞の枯渇を誘発し,CCL5とIL-10を上調する.
- 抗EBI3ヘプタペプチドはEBI3誘発のT細胞枯渇を成功裏に逆転させました.
結論:
- EBI3は,EBI3-STAT4-IL10/CCL5軸を通ってGCのT細胞枯渇を駆動する.
- EBI3は胃がんにおける免疫療法の強化のための新しい治療目標です.
- 開発された抗EBI3ヘプタペプチドは,GC治療における臨床応用の可能性を示しています.
さらに関連する動画
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
1.6K
07:20Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
14.8K
関連する概念動画
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
2.3K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.3K
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Tumor Immunotherapy
659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659
